Addition of sintilimab to pemetrexed and platinum improved progression-free survival

Denver–(Embargoed for 7 a.m. EST August 8, 2020)–The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented…

A Birthday at the Cemetery

We had barely clicked our seatbelts into place when my mother said, “Do you mind if we stop at the cemetery?” I knew my mom couldn’t bear to make the trek from where we lived in Monterey to the larger city of San Jose without paying her respects to my grandfather, but that afternoon was…

Live Coronavirus News: Global Tracker

Here’s what you need to know: ImageMark Meadows, the White House Chief of Staff, before gathering with other leaders in Speaker Nancy Pelosi’s office on Thursday.Credit…Gabriella Demczuk for The New York Times Negotiations to break the stimulus stalemate end with no compromise in sight. Top Democrats and the White House clashed anew on Thursday over…

SFU chemist’s new process fast-tracks drug treatments for viral infections and cancer

Discovering antiviral and anticancer drugs will soon be faster and cheaper thanks to new research from Simon Fraser University chemist Robert Britton and his international team. For the past 50 years, scientists have used manmade, synthetic and nucleoside analogues to create drug therapies for diseases that involve the cellular division and/or the viral reproduction of…